Zyvox, Linezolid News

Infectious Diseases / Bacteria / Viruses Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 , has started a Phase II clinical trial in adults with acute ...

The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid .

Under the agreement with Paratek Pharmaceuticals, a privately held company based in Boston, Massachusetts, the companies will share responsibility for developing PTK 0796.

Privately held Paratek Pharmaceuticals Inc. has found another partner to help develop its antibiotic PTK 0796 for life-threatening infections, this time joining with Swiss drugmaker Novartis AG in a deal valued at up to $485 million.

Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA.

Prabhavathi Fernandes says new antibiotic would fill a urgent medical need. View Larger Cempra Pharmaceuticals , which announced in May that it had raised $46 million in a third venture-capital round, is putting some of that money to use the way it said it would paying for clinical trials for the company's two product candidates.

Pfizer 's $2.3 billion settlement of the off-label Bextra case overshadows another case wrapped into the agreement, that of Ronald Rainero , a former district manager at Pfizer in New York City, regarding the antibiotic Zyvox .

Main Category: Respiratory / Asthma Also Included In: Infectious Diseases / Bacteria / Viruses ; Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 06 Aug 2009 - 0:00 PDT Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. , a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial of radezolid in the treatment of community-acquired pneumonia .

Rib-X Pharmaceuticals, Inc. , a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial of radezolid in the treatment of community-acquired pneumonia .

Main Category: Respiratory / Asthma Also Included In: Pharma Industry / Biotech Industry Infectious Diseases / Bacteria / Viruses Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. , a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial of radezolid in the treatment of community-acquired pneumonia .

The results of linezolid salvage therapy with or without carbapenem were compared with those of salvage therapy with vancomycin plus aminoglycosides or rifampicin.

The results of linezolid salvage therapy with or without carbapenem were compared with those of salvage therapy with vancomycin plus aminoglycosides or rifampicin.

Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, 200 milligrams Dosing over Five to Seven Days of Treatment SAN DIEGO , June 8 /PRNewswire/ -- Trius Therapeutics, Inc.

Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus Infections Data on frequency of resistance development and safety presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases SAN DIEGO, May 18 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical ...

From a recent Medscape report : On March 20, the FDA approved a new indication for tigecycline intravenous infusion , allowing its use for the treatment of community-acquired bacterial pneumonia caused by Streptococcus pneumonia , including cases with concurrent bacteremia, Haemophilus influenzae , and Legionella pneumophila.